HRP20020172A2 - Amino-triazolopyridine derivatives - Google Patents

Amino-triazolopyridine derivatives Download PDF

Info

Publication number
HRP20020172A2
HRP20020172A2 HR20020172A HRP20020172A HRP20020172A2 HR P20020172 A2 HRP20020172 A2 HR P20020172A2 HR 20020172 A HR20020172 A HR 20020172A HR P20020172 A HRP20020172 A HR P20020172A HR P20020172 A2 HRP20020172 A2 HR P20020172A2
Authority
HR
Croatia
Prior art keywords
pyridin
phenyl
triazolo
ylamine
furan
Prior art date
Application number
HR20020172A
Other languages
English (en)
Croatian (hr)
Inventor
Gerda Huber Trotmann
Walter Hunkeler
Roland Jakob-Roetne
Gavin John Kilpatrick
Matthias Heinrich Nettekoven
Claus Riemer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HRP20020172A2 publication Critical patent/HRP20020172A2/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HR20020172A 1999-09-06 2002-02-26 Amino-triazolopyridine derivatives HRP20020172A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99117578 1999-09-06

Publications (1)

Publication Number Publication Date
HRP20020172A2 true HRP20020172A2 (en) 2003-10-31

Family

ID=8238933

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020172A HRP20020172A2 (en) 1999-09-06 2002-02-26 Amino-triazolopyridine derivatives

Country Status (22)

Country Link
US (1) US6355653B1 (fr)
EP (1) EP1214322A2 (fr)
JP (1) JP2003528811A (fr)
KR (1) KR20020027625A (fr)
CN (1) CN1379777A (fr)
AR (1) AR037484A1 (fr)
AU (1) AU7511000A (fr)
BR (1) BR0013792A (fr)
CA (1) CA2383998A1 (fr)
CZ (1) CZ20021220A3 (fr)
HR (1) HRP20020172A2 (fr)
HU (1) HUP0203316A3 (fr)
IL (1) IL148167A0 (fr)
MA (1) MA26816A1 (fr)
MX (1) MXPA02001748A (fr)
NO (1) NO20021077L (fr)
PE (1) PE20010629A1 (fr)
PL (1) PL354240A1 (fr)
TR (1) TR200200579T2 (fr)
WO (1) WO2001017999A2 (fr)
YU (1) YU13502A (fr)
ZA (1) ZA200201055B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506772B1 (en) * 2000-12-15 2003-01-14 Hoffmann-La Roche Inc. Substituted [1,2,4]triazolo[1,5a]pyridine derivatives with activity as adenosine receptor ligands
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
US6693116B2 (en) * 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
MXPA04003277A (es) 2001-10-08 2004-07-23 Hoffmann La Roche Amida del acido 8-amino-?1,2,4?triazolo?1,5-a?piridina-6-carboxilico.
IL161573A0 (en) 2001-11-30 2004-09-27 Schering Corp [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS
HUP0105407A3 (en) * 2001-12-21 2004-04-28 Sanofi Aventis Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
EP2942082B1 (fr) 2002-01-28 2019-03-06 Kyowa Hakko Kogyo Co., Ltd Antagonistes des récepteurs a2a pour utilisation dans le traitement des troubles du mouvement
BR0312123A (pt) * 2002-06-13 2005-03-29 Pfizer Agentes de gnrh não peptìdicos, composições farmacêuticas e métodos para o seu uso
EP1711498A2 (fr) * 2004-01-26 2006-10-18 Altana Pharma AG 1,2,4-triazolo¬1,5-a|pyridines inhibant la secretion d'acide gastrique
WO2006068954A2 (fr) * 2004-12-21 2006-06-29 Schering Corporation Antagonistes de recepteur a2a de pyrazolo [1,5-a]pyrimidine adenosine
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
WO2008014199A2 (fr) * 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Composés modulant le récepteur cb2
BRPI0718515A2 (pt) * 2006-09-25 2013-11-19 Boehringer Ingelheim Int Compostos que modulam o receptor cb2
EA018036B1 (ru) * 2006-11-27 2013-05-30 Х. Лундбекк А/С Гетероариламидные производные
ATE495743T1 (de) 2006-12-01 2011-02-15 Galapagos Nv Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
NZ580394A (en) * 2007-04-10 2011-10-28 Lundbeck & Co As H Heteroaryl amide analogues as p2x7 antagonists
WO2009017954A1 (fr) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibiteurs de kinase jak2
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2704684A1 (fr) * 2007-11-07 2009-05-14 Boehringer Ingelheim International Gmbh Composes modulant le recepteur cb2
JP2011520884A (ja) * 2008-05-13 2011-07-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cb2受容体を変調するスルホン化合物
BRPI0910021A2 (pt) * 2008-06-20 2015-09-01 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinas em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
PE20110063A1 (es) * 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
JP5749162B2 (ja) * 2008-07-10 2015-07-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cb2受容体を調節するスルホン化合物
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
CN102164917A (zh) * 2008-09-25 2011-08-24 贝林格尔.英格海姆国际有限公司 选择性调节cb2受体的磺酰基化合物
MY153913A (en) * 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BRPI1009637A2 (pt) 2009-06-05 2019-04-30 Cephalon, Inc composto, composição e uso de um composto
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
US8383615B2 (en) 2009-06-16 2013-02-26 Boehringer Ingelheim International Gmbh Azetidine 2-carboxamide derivatives which modulate the CB2 receptor
PL2455381T3 (pl) * 2009-07-17 2014-10-31 Japan Tobacco Inc Triazolopirydynowy związek i jego działanie jako inhibitora hydroksylazy prolinowej i środka indukującego wytwarzanie erytropoetyny
WO2011037795A1 (fr) * 2009-09-22 2011-03-31 Boehringer Ingelheim International Gmbh Composés à modulation sélective du récepteur cb2
EP2523936A1 (fr) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Composés qui modulent le récepteur cb2
WO2011109324A1 (fr) 2010-03-05 2011-09-09 Boehringer Ingelheim International Gmbh Composés tétrazoles qui modulent sélectivement le récepteur cb2
JP5746764B2 (ja) 2010-07-22 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cb2受容体を調節する化合物
MX2014003025A (es) * 2011-09-19 2014-05-28 Hoffmann La Roche Compuestos de triazolopiridina como inhibidores de fosfodiesterasa 10a.
WO2013043518A1 (fr) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Composés imidazopyridyliques utilisables en tant qu'inhibiteurs de l'aldostérone synthase
EP2757883B1 (fr) * 2011-09-22 2021-01-13 Merck Sharp & Dohme Corp. Composés triazolopyridyle à utiliser en tant qu'inhibiteurs de l'aldostérone synthase
EP2803668A1 (fr) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Nouveau (cyano-dimethyl-methyl)-isoxazoles et - [1,3,4] thiadiazoles
CN109071444A (zh) 2016-03-16 2018-12-21 拜耳作物科学股份公司 作为农药和植物保护剂的n-(氰苄基)-6-(环丙基-羰基氨基)-4-(苯基)-吡啶-2-羧酰胺衍生物及相关化合物
CN106543175B (zh) * 2016-10-28 2018-06-01 上海大学 三芳基[1,2,4]三氮唑[1,5-a]吡啶衍生物及其制备方法
JP7111733B2 (ja) * 2017-03-16 2022-08-02 江蘇恒瑞医薬股▲ふん▼有限公司 ヘテロアリール[4,3-c]ピリミジン-5-アミン誘導体、その製造方法、およびその医薬の使用
CN112384515A (zh) 2018-02-27 2021-02-19 因赛特公司 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
MA52940A (fr) * 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
EP3818063A1 (fr) * 2018-07-05 2021-05-12 Incyte Corporation Dérivés de pyrazine fusionnés en tant qu'inhibiteurs d'a2a/a2b
WO2020054712A1 (fr) * 2018-09-12 2020-03-19 日本化薬株式会社 Agent de lutte contre les organismes nuisibles
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2022149167A1 (fr) * 2021-01-09 2022-07-14 Bugworks Research India Pvt Ltd Composés diaminopyrazolo [1,5-a] pyrimidine-6-carbonitrile utilisés comme antagoniste du récepteur de l'adénosine 2a et de l'adénosine 2b

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226735D0 (en) 1992-12-22 1993-02-17 Ici Plc Azole derivatives
AU2639299A (en) 1998-02-24 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Remedies/preventives for parkinson's disease

Also Published As

Publication number Publication date
NO20021077D0 (no) 2002-03-05
PL354240A1 (en) 2003-12-29
ZA200201055B (en) 2003-07-30
HUP0203316A2 (hu) 2003-01-28
NO20021077L (no) 2002-03-05
KR20020027625A (ko) 2002-04-13
AR037484A1 (es) 2004-11-17
US6355653B1 (en) 2002-03-12
HUP0203316A3 (en) 2004-07-28
CN1379777A (zh) 2002-11-13
TR200200579T2 (tr) 2002-12-23
IL148167A0 (en) 2002-09-12
YU13502A (sh) 2004-11-25
MXPA02001748A (es) 2002-08-06
WO2001017999A3 (fr) 2001-12-06
WO2001017999A2 (fr) 2001-03-15
CA2383998A1 (fr) 2001-03-15
AU7511000A (en) 2001-04-10
BR0013792A (pt) 2002-05-14
MA26816A1 (fr) 2004-12-20
PE20010629A1 (es) 2001-05-30
EP1214322A2 (fr) 2002-06-19
JP2003528811A (ja) 2003-09-30
CZ20021220A3 (cs) 2002-10-16

Similar Documents

Publication Publication Date Title
HRP20020172A2 (en) Amino-triazolopyridine derivatives
US9045428B2 (en) Substituted heterocyclic compounds
RU2277911C2 (ru) Модуляторы аденозиновых рецепторов
AU2002325316B2 (en) Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
US7592357B2 (en) Compounds
JP4782344B2 (ja) ベンザゾール誘導体と、そのjnkモジュレータとしての利用法
JP2006500362A (ja) 置換ピロロピリジン類
JP2014513078A (ja) パーキンソン病の治療方法及び治療用組成物
JP2017522277A (ja) 代謝型グルタミン酸受容体の負のアロステリックモジュレーター(nams)とその使用
KR100577109B1 (ko) 아데노신 수용체 리간드로서의 벤조티아졸 유도체
MX2013006054A (es) Compuestos de triazolopiridina.
TW202128677A (zh) Cd38抑制劑
JP4101755B2 (ja) 8−アミノ−〔1,2,4〕トリアゾロ〔1,5−a〕ピリジン−6−カルボン酸アミド
JP4101756B2 (ja) 5−メトキシ−8−アリール−〔1,2,4〕トリアゾロ〔1,5−a〕ピリジン誘導体
CN100372844C (zh) 作为腺苷受体配体的2-咪唑-苯并噻唑
AU2002347055A1 (en) Substituted Triazolopyridine Compounds
KR101586714B1 (ko) 피라졸 화합물
JPS62135475A (ja) 2−置換−e−融合−〔1,2,4〕トリアゾロ−〔1,5−C〕ピリミジン

Legal Events

Date Code Title Description
A1OB Publication of a patent application
OBST Application withdrawn